NO20084634L - Oral sammensetnig omfattende 3-(5-(4-(cyklopentyloksy)-2-hydroksybenzoyl)-2-((3-hydrolsy-1,2-benzisoksazol-6-yl) metoksy) fenyl) propionsyre eller salt derav - Google Patents

Oral sammensetnig omfattende 3-(5-(4-(cyklopentyloksy)-2-hydroksybenzoyl)-2-((3-hydrolsy-1,2-benzisoksazol-6-yl) metoksy) fenyl) propionsyre eller salt derav

Info

Publication number
NO20084634L
NO20084634L NO20084634A NO20084634A NO20084634L NO 20084634 L NO20084634 L NO 20084634L NO 20084634 A NO20084634 A NO 20084634A NO 20084634 A NO20084634 A NO 20084634A NO 20084634 L NO20084634 L NO 20084634L
Authority
NO
Norway
Prior art keywords
benzisoxazol
hydroxybenzoyl
cyclopentyloxy
methoxy
hydroxy
Prior art date
Application number
NO20084634A
Other languages
English (en)
Norwegian (no)
Inventor
Sahoe Kakuda
Tatsuhito Yahata
Masashi Kaneko
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of NO20084634L publication Critical patent/NO20084634L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20084634A 2006-05-26 2008-11-04 Oral sammensetnig omfattende 3-(5-(4-(cyklopentyloksy)-2-hydroksybenzoyl)-2-((3-hydrolsy-1,2-benzisoksazol-6-yl) metoksy) fenyl) propionsyre eller salt derav NO20084634L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006146315 2006-05-26
JP2006146257 2006-05-26
PCT/JP2007/060671 WO2007138997A1 (ja) 2006-05-26 2007-05-25 ３－｛５－［４－（シクロペンチルオキシ）－２－ヒドロキシベンゾイル］－２－［（３－ヒドロキシ－１，２－ベンズイソオキサゾール－６－イル）メトキシ］フェニル｝プロピオン酸またはその塩を含有する経口用組成物

Publications (1)

Publication Number Publication Date
NO20084634L true NO20084634L (no) 2008-12-19

Family

ID=38778517

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084634A NO20084634L (no) 2006-05-26 2008-11-04 Oral sammensetnig omfattende 3-(5-(4-(cyklopentyloksy)-2-hydroksybenzoyl)-2-((3-hydrolsy-1,2-benzisoksazol-6-yl) metoksy) fenyl) propionsyre eller salt derav

Country Status (21)

Country Link
US (1) US8093289B2 (sl)
EP (1) EP2022497B1 (sl)
JP (1) JP5161077B2 (sl)
KR (1) KR101394121B1 (sl)
CN (1) CN101454003B (sl)
AU (1) AU2007268772B2 (sl)
BR (1) BRPI0709710A2 (sl)
CA (1) CA2653023C (sl)
CY (1) CY1115312T1 (sl)
DK (1) DK2022497T3 (sl)
ES (1) ES2463455T3 (sl)
IL (1) IL195417A (sl)
MX (1) MX2008015015A (sl)
NO (1) NO20084634L (sl)
NZ (1) NZ573035A (sl)
PL (1) PL2022497T3 (sl)
PT (1) PT2022497E (sl)
RU (1) RU2436576C2 (sl)
SI (1) SI2022497T1 (sl)
WO (1) WO2007138997A1 (sl)
ZA (1) ZA200810018B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109476A1 (en) * 2008-03-04 2009-09-11 F. Hoffmann-La Roche Ag Process for preparing concentrated aqueous micellar solutions
PT2258361E (pt) * 2008-03-27 2014-10-15 Toyama Chemical Co Ltd Utilização de uma combinação de um derivado de benzofenona ou de um seu sal com um inibidor de tnfalfa e composição farmacêutica contendo o referido sal ou derivado e o inibidor
WO2009131098A1 (ja) 2008-04-22 2009-10-29 富山化学工業株式会社 ベンゾフェノン誘導体またはその塩および免疫抑制剤を組み合わせて使用する方法ならびにこれらを含有する医薬組成物
EP2140861A1 (en) 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
US20140100236A1 (en) * 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
CN110575762B (zh) * 2018-06-07 2024-03-26 温州大学新材料与产业技术研究院 一种有机烷基钆水性分散体系的制备方法
WO2021257887A1 (en) * 2020-06-19 2021-12-23 The Board Of Trustees Of The Leland Stanford Junior University Use of inhibitors of the activator protein 1 (ap-1) for preventing adhesions
JP7495340B2 (ja) 2020-12-16 2024-06-04 株式会社ファンケル カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3670080A (en) * 1969-03-06 1972-06-13 Shionogi & Co Process for stabilization of a composition of 2{60 ,3{60 -epithio-androstanes and composition obtained thereby
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
JPS56110612A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
JPS5942313A (ja) * 1982-09-01 1984-03-08 Teijin Ltd ポリビニルポリピロリドンを用いた製剤
JPS60190723A (ja) * 1984-03-09 1985-09-28 Yamanouchi Pharmaceut Co Ltd 難溶性薬物の溶解速度向上方法
CA2467261C (en) 2001-11-16 2010-10-12 Toyama Chemical Co., Ltd. Novel benzophenone derivatives or salts thereof

Also Published As

Publication number Publication date
NZ573035A (en) 2010-08-27
DK2022497T3 (da) 2014-05-19
ES2463455T3 (es) 2014-05-28
JPWO2007138997A1 (ja) 2009-10-08
KR20090021167A (ko) 2009-02-27
CY1115312T1 (el) 2017-01-04
RU2436576C2 (ru) 2011-12-20
ZA200810018B (en) 2010-02-24
AU2007268772B2 (en) 2012-03-15
AU2007268772A1 (en) 2007-12-06
BRPI0709710A2 (pt) 2011-07-26
US8093289B2 (en) 2012-01-10
IL195417A (en) 2014-03-31
CA2653023C (en) 2015-07-07
EP2022497A1 (en) 2009-02-11
JP5161077B2 (ja) 2013-03-13
EP2022497A4 (en) 2013-02-13
RU2008151757A (ru) 2010-07-10
WO2007138997A1 (ja) 2007-12-06
PT2022497E (pt) 2014-07-17
KR101394121B1 (ko) 2014-05-14
EP2022497B1 (en) 2014-04-30
CN101454003A (zh) 2009-06-10
IL195417A0 (en) 2009-08-03
CA2653023A1 (en) 2007-12-06
PL2022497T3 (pl) 2014-09-30
MX2008015015A (es) 2008-12-05
US20090163562A1 (en) 2009-06-25
SI2022497T1 (sl) 2014-08-29
CN101454003B (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
NO20084634L (no) Oral sammensetnig omfattende 3-(5-(4-(cyklopentyloksy)-2-hydroksybenzoyl)-2-((3-hydrolsy-1,2-benzisoksazol-6-yl) metoksy) fenyl) propionsyre eller salt derav
NZ592603A (en) Aryl gpr120 receptor agonists and uses thereof
KR100889894B1 (ko) 이소옥사졸린 유도체 및 이것을 유효성분으로 하는 제초제
JP2010533722A5 (sl)
JP2010523692A5 (sl)
PE20081199A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
HRP20120703T1 (hr) Novi intermedijeri korisni za pripremu alfa-(n-sulfonamido)acetamido spoja
JP2010521514A5 (sl)
NZ581698A (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
RS51959B (en) FUNGICID MIXTURES
EA200600381A1 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение в качестве лекарственного средства
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20071062A1 (es) Antibioticos de carbonatos de fenicol
DK1874762T3 (da) Fremgangsmåde til fremstilling af 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamid
MY144770A (en) Polishing composition
JP2009501704A5 (sl)
PL378130A1 (pl) Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
IL200401A0 (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
ATE362367T1 (de) Phenoxyessigsäure-derivate als peroxisom- proliferator-aktivierte rezeptor (ppar) dual- agonisten
JP2004506721A5 (sl)
RS51517B (en) NEW CRYSTAL 3- [5- [4- (Cyclopentyloxy] -2-hydroxybenzoyl] -2 - [(3-hydroxy-1,2-benzisoxazol-6-yl) methoxy] phenyl] propionic acids
PE20080554A1 (es) Formulacion acuosa del acido 4-[((4-carboxibutil)-{2-[(4-fenetilbencil)oxi]fenil}amino)metil]benzoico
JP2010527364A5 (sl)
ATE475642T1 (de) Phenoxyessigsäurederivate als ppar-agonisten
CY1115787T1 (el) Διαδικασια για την παραγωγη 3-[5-[4-(κυκλοπεντυλοξυ)-2-υδροξυβενζοϋλο]-2-[(3-υδροξυ-1,2-βενζισοξαζολ-6-υλο)μεθοξυ]φαινυλο]προπιονικου εστερα και ενδιαμεση για την διαδικασια